Какова цена за Prometheus Biosciences, Inc. (RXDX)

Цена за Prometheus Biosciences, Inc. (RXDX) Это $199.92

Какова рыночная капитализация для Prometheus Biosciences, Inc. (RXDX)

Рыночная капитализация для Prometheus Biosciences, Inc. (RXDX) Это $5.39B

Prometheus Biosciences, Inc. (RXDX) История Цен

Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.

Год	Результативность
2023	108.72%
2022	183.53%
2021	0.00%

Год

Результативность

2023

108.72%

2022

183.53%

2021

0.00%

Компания	Цена акций	Изменение 1г%	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$553.09	42.85%	US
Argenx SE ARGX.US	$1.02K	44.02%	NL
Moderna, Inc. MRNA.US	$158.64	541.49%	US
CSL Limited CSL.AX	$122.23	-12.55%	AU
Lonza Group AG LONN.SW	$772.27	7.33%	CH

Компания

Цена акций

Изменение 1г%

Страна